{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T05:42:53Z","timestamp":1776058973911,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pleomorphic invasive lobular carcinoma (PLC) is a rare and aggressive subtype of invasive lobular carcinoma. When it presents with an inflammatory breast cancer (IBC) phenotype, due to its rarity, this can lead to substantial diagnostic and therapeutic challenges. Herein, we report the case of a 53-year-old woman presenting with a rapidly enlarging left breast mass, diffuse edema, erythema, and pain; these symptoms have affected the entire breast over the course of one month. Imaging revealed diffuse parenchymal abnormalities and nodal involvement, while biopsy indicated PLC, histologic grade III, with HER2 amplification and complete absence of hormone receptors. Clinical and radiological assessment demonstrated nodal involvement (supraclavicular, cervical, and bilateral axillary) and distant osseous metastases, consistent with stage cT4N3M1 disease. The patient received first-line docetaxel, trastuzumab, and pyrotinib (PyroHT) and achieved a partial response; however, progression was observed after ten cycles. Following multidisciplinary review, her treatment was changed to trastuzumab deruxtecan (T-DXd), resulting in significant symptom relief and radiologic regression of the breast lesions. This case highlights the importance of early biopsy in rapidly progressive breast disease and that treatment for rare histologic subtypes, such as PLC, should be guided by molecular profiling rather than histology alone. Sequential HER2-targeted therapy provided meaningful clinical benefit, though resistance ultimately developed. We present the case of a 53-year-old woman with HER2-positive advanced PLC presenting with an IBC phenotype, providing insight into the diagnostic process and treatment course in this rare clinical scenario.<\/jats:p>","DOI":"10.3389\/fonc.2026.1810319","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:46:32Z","timestamp":1776055592000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare overlap of subtype and phenotype: HER2-positive pleomorphic invasive lobular carcinoma presenting with an inflammatory breast cancer phenotype: a case report and targeted treatment strategy"],"prefix":"10.3389","volume":"16","author":[{"given":"Zhifeng","family":"Xiong","sequence":"first","affiliation":[{"name":"Department of Breast, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gendou","family":"Zhou","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Chongqing University Fuling Hospital","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Na","family":"Zhou","sequence":"additional","affiliation":[{"name":"College of Nursing, Chongqing Medical and Pharmaceutical College","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luyao","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Breast, The Third Affiliated Hospital of Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Breast, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Breast, The Third Affiliated Hospital of Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Breast, Chongqing Hospital of Traditional Chinese Medicine","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70061","article-title":"Lobular breast cancer statistics, 2025","volume":"131","author":"Giaquinto","year":"2025","journal-title":"Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.64.0334","article-title":"Genomic characterization of primary invasive lobular breast cancer","volume":"34","author":"Desmedt","year":"2016","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2025.109714","article-title":"Invasive pleomorphic lobular carcinoma of the breast: Clinicopathological features, treatment patterns and outcomes","volume":"51","author":"Peradze","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1177\/00031348241241612","article-title":"Comparison of clinicopathological features of pleomorphic and invasive lobular breast carcinomas","volume":"90","author":"Sa\u011fd\u0131\u00e7","year":"2024","journal-title":"Am Surgeon\u2122"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-014-2861-6","article-title":"Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma","volume":"144","author":"Loibl","year":"2014","journal-title":"Breast Cancer Res Treat"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jare.2020.08.014","article-title":"Update on systemic treatment for newly diagnosed inflammatory breast cancer","volume":"29","author":"Chainitikun","year":"2021","journal-title":"J Adv Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06434-x","article-title":"Inflammatory breast cancer defined: Proposed common diagnostic criteria to guide treatment and research","volume":"192","author":"Jagsi","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B8","article-title":"Inflammatory breast cancer","volume-title":"StatPearls","author":"Chippa","year":"2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-022-06627-y","article-title":"Biomarker profile of invasive lobular carcinoma: Pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses","volume":"194","author":"Zhang","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-023-06927-x","article-title":"HER-2 low status in early-stage invasive lobular carcinoma of the breast: Associated factors and outcomes in an institutional series","volume":"199","author":"Rothschild","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01935-8","article-title":"Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: A single-arm, phase 2 trial","volume":"28","author":"Bartsch","year":"2022","journal-title":"Nat Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/tbcr-25-8","article-title":"Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses","volume":"6","author":"Wu","year":"2025","journal-title":"Trans Breast Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0145534","article-title":"Inflammatory breast cancer: A distinct clinicopathological entity transcending histological distinction","volume":"11","author":"Raghav","year":"2016","journal-title":"PloS One"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000002446","article-title":"The clinicopathologic features of inflammatory breast carcinoma (IBC) with lobular features","volume":"49","author":"Bachert","year":"2025","journal-title":"Am J Surg Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-018-6486-6","article-title":"Eighth edition of the AJCC cancer staging manual: Breast cancer","volume":"25","author":"Giuliano","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s13193-024-02094-7","article-title":"How to define inflammatory breast cancer: A systematic review","volume":"16","author":"Alipour","year":"2025","journal-title":"Indian J Surg Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15225491","article-title":"Lobular carcinoma of the breast: A comprehensive review with translational insights","volume":"15","author":"Batra","year":"2023","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.25122\/jml-2022-0213","article-title":"HER2\/positive and HER2\/low in inflammatory breast cancer recurrence","volume":"15","author":"Movchan","year":"2022","journal-title":"J Med Life"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1276637","article-title":"Bilateral inflammatory recurrence of HER-2 positive breast cancer: A unique case report and literature review","volume":"14","author":"Qin","year":"2024","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1113216","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076065","article-title":"Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): Randomised, double blind, multicentre, phase 3 trial","volume":"383","author":"Ma","year":"2023","journal-title":"BMJ"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf296","article-title":"Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: A multicenter real-world study","volume":"30","author":"Li","year":"2025","journal-title":"Oncologist"},{"key":"B23","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1186\/s12916-022-02708-3","article-title":"Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): A double-blind, randomized phase 3 trial","volume":"20","author":"Wu","year":"2022","journal-title":"BMC Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231217972","article-title":"Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: A multicenter, retrospective study","volume":"15","author":"You","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000038508","article-title":"HER2\/PI3K\/AKT pathway in HER2-positive breast cancer: A review","volume":"103","author":"Pan","year":"2024","journal-title":"Medicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf277","article-title":"Pyrotinib versus pertuzumab with trastuzumab and taxane in HER2-positive metastatic breast cancer: A Chinese multicenter real-world study","volume":"30","author":"Liu","year":"2025","journal-title":"Oncologist"},{"key":"B28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13058-025-02062-1","article-title":"Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States","volume":"27","author":"Odzer","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1890710","article-title":"Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond","volume":"21","author":"Perez","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/nejmoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac107","article-title":"Clinical practices and institutional protocols on prophylaxis, monitoring, and management of selected adverse events associated with trastuzumab deruxtecan","volume":"27","author":"Bardia","year":"2022","journal-title":"Oncologist"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112152-20231122-00319","article-title":"Chinese expert consensus on the management of clinical pathway and adverse events of trastuzumab deruxtecan (2024 edition)","volume":"46","year":"2024","journal-title":"Zhonghua Zhong Liu Za Zhi"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1810319\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T04:46:51Z","timestamp":1776055611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1810319\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,13]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1810319"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1810319","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,13]]},"article-number":"1810319"}}